News - Alkermes

Filter

Current filters:

Alkermes

Popular Filters

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

Alkermes reveals candidates for MS, cancer and pain

18-07-2013

US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

Alkermes boosted by positive Ph II data on ALKS 5461 for major depressive disorder

18-04-2013

Ireland-headquartered Alkermes (Nasdaq: ALKS) saw its shares rise 16% to $29.72, after it announced positive…

AlkermesNeurologicalPharmaceuticalResearch

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

Elan cashes in 76% chunk of its Alkermes stake for $381 million; Roche updates on Illumina bid

14-03-2012

Ireland-based Elan Corp (NYSE: ELN) revealed yesterday that it has raised around $381 million in net…

AlkermesElanElan Drug TechnologiesFinancialIlluminaMergers & AcquisitionsPharmaceuticalRoche

Alkermes pulls MAA for Megestrol product

13-03-2012

The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker…

AlkermesAnti-viralsEuropeMegestrolOncologyPharmaceuticalRegulation

2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

03-02-2012

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

FDA finally approves Bydureon

30-01-2012

There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Strong results for Alkermes’ ALKS 5461 in major depressive disorder

04-01-2012

US drugmaker Alkermes (Nasdaq: ALKS) yesterday released positive early clinical results for a central…

AlkermesAripiprazoleNeurologicalPharmaceuticalResearch

Alkermes completes Elan DT buy; signs manufacturing deal

19-09-2011

US drugmaker Alkermes (Nasdaq: ALKS) says it has now completed its previously-announced acquisition of…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

13-09-2011

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Alkermes shareholders vote in favor of merger with Elan Drug Technology

09-09-2011

Shareholders of USA-based Alkermes (Nasdaq; ALKS) have voted to approve the previously-announced $960…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

US FDA sets PDUFA action dates for Bydureon and peginesatide

12-08-2011

US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Amylin and Eli Lilly submit CRL reply on Bydureon to US FDA

29-07-2011

US biotech Amylin Pharmaceuticals (Nasdaq: AMLN), drug major Eli Lilly (NYSE: LLY) and partner Alkermes…

AlkermesAmylinBiotechnologyBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Back to top